Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
627 clinical trials found
Clinical trials

CARTITUDE-6

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (EMN28 68284528MMY3005) (NCT05257083)

Currently recruiting

CASPER

Colchicine After Stroke to Prevent Event Recurrence (CASPER) A randomised trial to evaluate the efficacy of oral Colchicine in high-risk patients with atherosclerosis-associated inflammation post-Stroke (ACTRN12621001408875)

Currently recruiting

CAST BM12

Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis (ACTRN12618000505202)

Currently recruiting

CC93538-EE-001

A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic Esophagitis (NCT04753697)

No longer recruiting

CC93538-EE-002

A Phase 3, Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term safety of CC-93538 in Adult and adolescent subjects with eosinophilic esophagitis. (NCT04991935)

Currently recruiting

CCTL019E2301

A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma (NCT05888493)

Currently recruiting

CEC-4/CEL

A phase IIb, double-blind, randomised, placebo-controlled trial evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet (ISRCTN79155276)

Currently recruiting

CECI830A12101

An open-label, multi-center, phase I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors (NCT06726148)

Currently recruiting

CELEBRATE

A Phase 1B study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF-mutant metastatic melanoma (The CELEBRATE study) (NCT04720768)

No longer recruiting

Celldex CDX0159-13

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment [EMBARQ – CSU2] (NCT06455202)

The CDX0159-13 study is designed to evaluate the safety and efficacy of Barzolvolimab in adult participants with chronic spontaneous urticaria (CSU) who still have symptoms despite H1-antihistamine treatment. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered as injections under the skin (subcutaneous). The treatment period will be approximately 52 weeks with all participants moved to active treatment (receiving treatment drug) after Week 24.

Currently recruiting

CG_MAGIC

Continuous Glucose Monitoring to Achieve euGlycemia in Cystic Fibrosis (Trial Not Registered)

Currently recruiting

CHAMPIONSHIP Trial

First In Human Study to Assess Safety and Efficacy of the ChampioNIR Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease (NCT06410313)

Peripheral arterial disease (PAD) is a condition which leads to narrowing and blockages in the large and medium-sized arteries which supply blood to your leg which typicalling requires angioplasty treatment. The ChampioNIR DES is a stent made of metal, coated with a mesh that can expand and which contains a drug called ridaforolimus. . Ridaforolimus stops cells from growing and replicating by attaching to a protein called mTOR, meaning that cells are less likely to build up around your stent and narrow your arteries.
Coming soon

CHARM

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction (NCT02864953)

Currently recruiting

CHECK MATE 9DW

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma (NCT04039607)

Currently recruiting

Chugai DQB103CT

A PHASE IC, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, IMMUNOGENICITY, AND BIOLOGICAL EFFECTS OF DONQ52 IN CELIAC DISEASE PATIENTS WITH GLUTEN CHALLENGE (NCT05425446)

Currently recruiting

CIP 12-19 fMRI

Pilot study: A comparison of rehabilitation success following primary vs secondary targeted muscle re-innervation surgery using functional magnetic resonance imaging analysis in upper and lower extremity amputees (Trial Not Registered)

Currently recruiting

CJSB462B12201

A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) (NCT07047118)

This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
Currently recruiting

CL1-95035-001

A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP (NCT06188702)

Currently recruiting

CLB-4000-1-001

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B (ACTRN12625000204448)

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B
Currently recruiting

CLEOPATTRA

CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy [ATTR-CM] (NCT07207811)

This study aims to determine whether a new medication, NNC6019-0001, can lower the risk of heart-related complications in people diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease that affects the heart. Participants will be randomly assigned to receive either NNC6019-0001 or a placebo, which contains no active drug. Throughout the study, all participants will continue their standard heart treatments as advised by their healthcare provider.
Coming soon
6 7 8 9 10